^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ARC 100

    i
    Other names: ARC 100, NBT 287, TPI 287, TPI-287, TPI287, ARC100, ARC-100, NBT-287, NBT287
    Associations

    News

    Trials
    Company:
    Cortice Biosci
    Drug class:
    Tubulin polymerization inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    The CNS-penetrating taxane drug TPI 287 potentiates antiglioma activity of the AURKA inhibitor alisertib in vivo. (PubMed, Cancer Chemother Pharmacol)
    Results suggest that apoptosis is the dominant mechanism of potentiation of GBM growth inhibition by alisertib + TPI 287, in part through effects on Bcl-2 family proteins, providing a rationale for further laboratory testing of an AURKA inhibitor plus TPI 287 as a potential therapy against GBM.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • ANXA5 (Annexin A5)
    |
    alisertib (MLN8237) • ARC 100